The first generation of mAbs, unveiled in 1975 (ref. 1), were murine mAbs derived from mouse B-cell hybridomas (see “Monoclonal antibodies by design”). However, as murine mAbs moved into ...

examined the efficacy of two novel anti-osteopontin monoclonal antibodies (mAbs; 23C3 and F8E11) in the treatment of murine collagen-induced arthritis (CIA), an animal model of human RA.

These engineered antibodies can convert proteins from a threat recognition agent, into a disease-fighting form. Transgenic mice allow researchers to create “humanized” mice with human equivalents of ...

The mAbs that have been used in the clinic include murine, chimeric, humanized and fully human antibodies. In particular, chimerization consists of the replacement of the mouse constant domains ...

a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre ...

a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre ...